New drug-eluting stents very promising

December 5, 2017 by Berend Meijering

New-generation stents containing anti-vasoconstriction medication perform well. They are safe and efficient for most patients, over both the short term and the long term. According to Liefke van der Heijden, a trainee cardiologist at the Medisch Spectrum Twente hospital, future research into stents may focus on high-risk patients or those with complex lesions. She will be awarded a PhD by the University of Twente's Faculty of Behavioural, Management and Social Sciences (BMS) on Wednesday 6 December. Her doctoral thesis is titled Second-generation drug-eluting stents and beyond.

Drug-eluting (DES) have become an indispensable element in the treatment of constrictions. In many cases, keeping coronary arteries open by inserting small, drug-containing tubes is an alternative to major heart bypass surgery. The steady stream of new developments means that stents are progressively becoming safer and more effective. Second-generation stents are already outperforming the first generation devices. They are biocompatible, so there is less risk of an inflammatory reaction, of blood vessel constriction, and of potential new constrictions developing in the coronary artery. The ongoing development of stents has brought an added benefit – the platforms have become more flexible, which has made it much easier to position them. This is particularly useful in the treatment of coronary artery constrictions where the type and extent of the lesions involved makes it more difficult to position the stent.

Dr Van der Heijden's research focuses on second generation , and the more recent generations. Both short-term and long-term follow-up show excellent results in terms of safety and effectiveness. Her doctoral thesis also covers the latest research in this area. The stents that are currently under development include a category that is partially bioresorbable (biologically soluble) and another that is completely bioresorbable. The partially bioresorbable stents are already showing good short-term results. However, there is some debate concerning the safety of the first generation of fully bioresorbable stents. In theory, they are very promising but, as yet, nothing is known about their potential long-term benefits. Studies are needed to find out how their short-term results can be improved.

After stenting, some patients are at greater risk of an adverse outcome than others. These tend to be patients who have had previous bypass surgery, patients whose treatment involved small vessels, patients with highly calcified coronary and with a constriction at the point where a coronary artery branches. Certain stent properties could provide better clinical outcomes for these groups in particular. This University of Twente PhD candidate feels that, given the high risk of blood vessel constriction (or re-constriction), future research should ideally focus on this patient population in particular.

Explore further: New drug-eluting stents more effective

Related Stories

New drug-eluting stents more effective

July 15, 2014
Research conducted by University of Twente PhD candidate Kenneth Tandjung has shown that the new generation of drug-eluting stents, which is being used in coronary angioplasty to open narrowed coronary arteries, is safe and ...

Cardiologist warns against dissolvable stents in NEJM

April 6, 2017
In a New England Journal of Medicine (NEJM) editorial published last week, Debabrata Mukherjee, M.D., provides expert commentary on bioresorbable stents, an alternative to the traditional stents used in patients with cardiac ...

Results from the BIO-RESORT trial presented

October 31, 2016
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in ...

Results of DUTCH PEERS (TWENTE II) trial reported

October 31, 2013
Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish ...

Drug-eluting stents more benefit in saphenous vein graft

August 30, 2016
Drug-eluting stents had a clear advantage over bare metal stents in patients undergoing revascularisation of saphenous (leg) vein grafts, results of the BASKET-SAVAGE trial show.

EuroPCR issues statement on bioresorbable stent (BRS) technologies

May 22, 2017
Ongoing development of bioresorbable stent (BRS) technologies that are bioresorbed after achieving vessel expansion in percutaneous coronary intervention procedures is an important option to optimise outcomes in patients ...

Recommended for you

Scientists rewrite our understanding of how arteries mend

December 13, 2017
Scientists from The University of Manchester have discovered how the severity of trauma to arterial blood vessels governs how the body repairs itself.

Deadly heart rhythm halted by noninvasive radiation therapy

December 13, 2017
Radiation therapy often is used to treat cancer patients. Now, doctors at Washington University School of Medicine in St. Louis have shown that radiation therapy—aimed directly at the heart—can be used to treat patients ...

Ultra-thin tissue samples could help to understand and treat heart disease

December 12, 2017
A new method for preparing ultra-thin slices of heart tissue in the lab could help scientists to study how cells behave inside a beating heart.

Research reveals how diabetes in pregnancy affects baby's heart

December 12, 2017
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels—whether caused by diabetes or other factors—keep heart cells from maturing ...

Young diabetics could have seven times higher risk for sudden cardiac death

December 12, 2017
Young diabetics could have seven times more risk of dying from sudden cardiac arrest than their peers who don't have diabetes, according to new research.

Blood flow–sensing protein protects against atherosclerosis in mice

December 12, 2017
UCLA scientists have found that a protein known as NOTCH1 helps ward off inflammation in the walls of blood vessels, preventing atherosclerosis—the narrowing and hardening of arteries that can cause heart attacks and strokes. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.